Coffey CM, Richter MD, Crowson CS, et al. - In this study, researchers defined the indication, outcomes, and adverse effects of rituximab (RTX) treatment in a large single-center cohort of individuals with systemic rheumatoid vasculitis (RV). A retrospective review was designed to include the medical charts of 17 individuals treated with RTX for systemic RV between 2000 and 2017. They examined clinical characteristics, outcomes, and adverse effects. In the analysis, mean age was 59 years , 59% were female, 94% were white, and 82% had positive rheumatoid factor, at RV diagnosis. There is difficulty to treat systemic RV effectively. The data revealed that CR of RV was in 62% and partial response in 38% of individuals within 12 months of RTX use. Future data is required to inform treatment for individuals with RV.